XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Revenue $ 550,000  
Costs and expenses:    
Research and development 3,812,000 $ 2,966,000
General and administrative 1,724,000 1,628,000
Total costs and expenses 5,536,000 4,594,000
Loss from operations (4,986,000) (4,594,000)
Interest expense 0 (1,000)
Other income (expense), net 24,000  
Loss before provision for income taxes (4,962,000) (4,595,000)
Provision for income taxes 0 0
Comprehensive loss $ (4,962,000) $ (4,595,000)
Net loss per share attributable to Vaccinex, Inc. common stockholders, basic $ (0.10) $ (0.12)
Net loss per share attributable to Vaccinex, Inc. common stockholders, diluted $ (0.10) $ (0.12)
Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic 49,880,761 38,758,283
Weighted-average shares used in computing net loss per share attributable toVaccinex, Inc. common stockholders, diluted 49,880,761 38,758,283